Senzime is currently carrying out a rights issue with preferential rights for existing shareholders. The subscription price is set to SEK 5.40 per share and the subscription period is March 14-28. All information on the issue are gathered at Redeye transaction
Senzime is building a global leader in patient monitoring, an area which continues to gain ground in pace with increased demands for patient safety and lower health care costs. As part of this strategy, the company continues with product development, clinical verification, sharpen the patent portfolio and strengthen the organization to build the new Senzime. The company has a unique and competitive portfolio of products in patient monitoring with expected market launch 2017.
You are most welcome to contact us for a dialog on scientific collaborations, partnering or product distribution.
Extern analysis, Redeye